Therefore, we do not expect that excluding loss of efficacy has affected our overall results much since efficacy was included in the intermediate outcome (which was a composite of death, cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke) for the most predominant DGI (clopidogrel-CYP2C19). This evidence concerns the gene CYP2C19 and stroke disorder.